B
3.28
1.41 (75.40%)
| 前收盘价格 | 1.87 |
| 收盘价格 | 3.79 |
| 成交量 | 105,826,173 |
| 平均成交量 (3个月) | 4,037,145 |
| 市值 | 4,900,917 |
| 市盈率 (P/E TTM) | 0.007 |
| 价格/销量 (P/S) | 54.99 |
| 股市价格/股市净资产 (P/B) | 0.450 |
| 52周波幅 |
| 稀释每股收益 (EPS TTM) | 277.20 |
| 总债务/股东权益 (D/E MRQ) | 5.17% |
| 流动比率 (MRQ) | 2.71 |
| 营业现金流 (OCF TTM) | -6.70 M |
| 杠杆自由现金流 (LFCF TTM) | -4.55 M |
| 资产报酬率 (ROA TTM) | -80.05% |
| 股东权益报酬率 (ROE TTM) | -200.56% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 看跌 |
| Medical Devices (全球的) | 混合的 | 看跌 | |
| 股票 | Bluejay Diagnostics, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
0.8
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.83 |
|
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Value |
| 内部持股比例 | 0.26% |
| 机构持股比例 | 2.48% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合